Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6–deficient process
Piers E.M. Patten, … , Charles C. Chu, Nicholas Chiorazzi
Piers E.M. Patten, … , Charles C. Chu, Nicholas Chiorazzi
Published April 7, 2016
Citation Information: JCI Insight. 2016;1(4):e86288. https://doi.org/10.1172/jci.insight.86288.
View: Text | PDF
Research Article Hematology Immunology

Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6–deficient process

  • Text
  • PDF
Abstract

Xenografting primary tumor cells allows modeling of the heterogeneous natures of malignant diseases and the influences of the tissue microenvironment. Here, we demonstrate that xenografting primary chronic lymphocytic leukemia (CLL) B lymphocytes with activated autologous T cells into alymphoid mice results in considerable CLL B cell division and sizable T cell expansion. Nevertheless, most/all CD5+CD19+ cells are eventually lost, due in part to differentiation into antibody-secreting plasmablasts/plasma cells. CLL B cell differentiation is associated with isotype class switching and development of new IGHV-D-J mutations and occurs via an activation-induced deaminase-dependent pathway that upregulates IRF4 and Blimp-1 without appreciable levels of the expected Bcl-6. These processes were induced in IGHV-unmutated and IGHV-mutated clones by Th1-polarized T-bet+ T cells, not classical T follicular helper (Tfh) cells. Thus, the block in B cell maturation, defects in T cell action, and absence of antigen-receptor diversification, which are often cardinal characteristics of CLL, are not inherent but imposed by external signals and the microenvironment. Although these activities are not dominant features in human CLL, each occurs in tissue proliferation centers where the mechanisms responsible for clonal evolution operate. Thus, in this setting, CLL B cell diversification and differentiation develop by a nonclassical germinal center–like reaction that might reflect the cell of origin of this leukemia.

Authors

Piers E.M. Patten, Gerardo Ferrer, Shih-Shih Chen, Rita Simone, Sonia Marsilio, Xiao-Jie Yan, Zachary Gitto, Chaohui Yuan, Jonathan E. Kolitz, Jacqueline Barrientos, Steven L. Allen, Kanti R. Rai, Thomas MacCarthy, Charles C. Chu, Nicholas Chiorazzi

×

Figure 1

Transfer of CLL B cells into NSG mice can lead to terminal differentiation of cells into plasmablasts/plasma cells.

Options: View larger image (or click on image) Download as PowerPoint
Transfer of CLL B cells into NSG mice can lead to terminal differentiati...
(A) Analysis of mCD45–hCD4–hCD8– cells from spleens reveals a hCD45+ subpopulation strongly expressing CD38 (CD38++) that are larger but with less CD19 (MFI: CD38++ = 1,178 vs. CD38– = 7,157) and CD5 (MFI: CD38++ = 8,508 vs. CD38– = 9,763) intensities. A CD38++ subset expresses CD138 (19.7%). When FACS-sorted, this population (*) used the clonal, patient-specific IGHV-D-J rearrangement. (B) Representative immunohistology (IH) of a CD20+PAX5+ perivascular aggregate (PVA). Arrow identifies vessel. Scale bar: 250 μm. (C) Representative IH of human IgM, IgG, Igκ, and Igλ in a CD20+PAX5+PVA. Scale bar: 250 μm. (D) Igκ staining of area indicated by arrow in C showing denser Ig at the CD20+PAX5+PVAs rims. H&E staining reveals a plasmablast/plasma cell (PC) morphology. Scale bar: 10 μm. (E) Representative H&E and IH of area with cells having PC morphology shows expression of CD38, PC-marker VS38c, and CD138 in a subset of cells. Scale bar: 50 μm. (F) Representative immunofluorescence staining of a CD20+PAX5+PVA rim, as indicated by arrows in C. Blue, nuclear stain; red, CD20; and green, Igκ. Scale bar: 10 μm. Preceding data derived from 13 chronic lymphocytic leukemia (CLL) cases in 13 independent experiments involving 51 mice with T cell expansion (Table 1). m, murine; h, human; MFI, mean fluorescence intensity; NSG, NOD/Shi-scid,γcnull; PVA, perivascular aggregate.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts